SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) traded down 1.8% during mid-day trading on Wednesday . The stock traded as low as $1.65 and last traded at $1.66. 1,169,980 shares changed hands during trading, a decline of 57% from the average session volume of 2,730,437 shares. The stock had previously closed at $1.69.
Wall Street Analysts Forecast Growth
Separately, Maxim Group increased their price objective on SELLAS Life Sciences Group from $4.00 to $7.00 and gave the company a "buy" rating in a report on Wednesday, July 16th.
Read Our Latest Research Report on SLS
SELLAS Life Sciences Group Stock Performance
The firm has a fifty day moving average price of $1.80 and a 200 day moving average price of $1.47. The stock has a market cap of $165.63 million, a PE ratio of -4.37 and a beta of 2.26.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. On average, equities research analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.
Insider Buying and Selling at SELLAS Life Sciences Group
In other SELLAS Life Sciences Group news, Director Jane Wasman purchased 20,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was purchased at an average price of $1.69 per share, for a total transaction of $33,800.00. Following the purchase, the director directly owned 30,400 shares in the company, valued at approximately $51,376. This trade represents a 192.31% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On SELLAS Life Sciences Group
Several institutional investors have recently bought and sold shares of SLS. Anson Funds Management LP grew its position in shares of SELLAS Life Sciences Group by 535.7% in the first quarter. Anson Funds Management LP now owns 7,579,095 shares of the company's stock valued at $8,185,000 after purchasing an additional 6,386,829 shares in the last quarter. Geode Capital Management LLC grew its position in shares of SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after purchasing an additional 128,355 shares in the last quarter. Brooklyn FI LLC purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $677,000. Northern Trust Corp grew its position in shares of SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock valued at $140,000 after purchasing an additional 33,878 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of SELLAS Life Sciences Group by 30.9% in the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after purchasing an additional 12,706 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors and hedge funds.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access